Apraclonidine should not be used in patients receiving MAO inhibitors.
Source: NLP:apraclonidine
Brand names: Apraclonidine
Route: Ophthalmic
Contraindications
CONTRAINDICATIONS Apraclonidine ophthalmic solution 0.5% is contraindicated in patients with hypersensitivity to apraclonidine or any other component of this medication, as well as systemic clonidine. It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitors.
Pregnancy & Breastfeeding
Pregnancy Apraclonidine HCl has been shown to have an embryocidal effect in rabbits when given in an oral dose of 3.0 mg/kg (60 times the maximum recommended human dose). Dose related maternal toxicity was observed in pregnant rats at 0.3 mg/kg (6 times the maximum recommended human dose). There are no adequate and well controlled studies in pregnant women. Apraclonidine ophthalmic solution 0.5% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
9 interactions on record
Apraclonidine should not be used in patients receiving MAO inhibitors.
Source: NLP:apraclonidine
Possibility of additive or potentiating effect with CNS depressants.
Source: NLP:apraclonidine
Possibility of additive or potentiating effect with CNS depressants.
Source: NLP:apraclonidine
Caution advised as apraclonidine may reduce pulse and blood pressure.
Source: NLP:apraclonidine
Caution advised with simultaneous use of clonidine and other similar pharmacologic agents.
Source: NLP:apraclonidine
Apraclonidine may inhibit catecholamine production in response to insulin-induced hypoglycemia and mask hypoglycemia signs.
Source: NLP:apraclonidine
Caution advised due to potential additive hypotensive and pulse-reducing effects.
Source: NLP:apraclonidine
Possibility of additive or potentiating effect with CNS depressants.
Source: NLP:apraclonidine
Possibility of additive or potentiating effect with CNS depressants.
Source: NLP:apraclonidine